250 results on '"Mazzotta, Marco"'
Search Results
2. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy
3. WCN24-788 IGA GLOMERULONEPHRITIS, RENAL CORTICAL NECROSIS AND A SYSTEMIC AUTOINFLAMMATORY DISEASE: COINCIDENCE OR CAUSATION? A CASE REPORT
4. Negative herpesvirus-8 immunoreactivity in Kaposi's sarcoma after liver transplantation
5. Exploring the role of respiratory microbiome in lung cancer: A systematic review
6. Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives
7. SYSTEMIC AUTOINFLAMMATORY DISEASE, IgA GLOMERULONEPHRITIS AND RENAL CORTICAL NECROSIS: COINCIDENCE OR CAUSATION?
8. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
9. Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors
10. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma
11. Transcriptional phenocopies of deleterious KEAP1 mutations dictate survival outcomes in lung cancer treated with immunotherapy.
12. Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians’ practice
13. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
14. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
15. Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
16. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
17. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
18. Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report
19. Tumor de células granulares o tumor de Abrikossoff en la zona pubiana: reporte de un caso
20. Real-Life Experience of the Prognostic Significance of the Primary Tumor Location on the Timing of Colorectal Liver Metastases: A Retrospective Analysis
21. The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
22. Metastatic anaplastic large cell lymphoma of the omentum presenting as an ulcerated nodule on the back
23. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer
24. Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer
25. Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
26. Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
27. Effects of the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine on immune-related adverse events and disease outcomes in cancer patients receiving immune checkpoint inhibitors
28. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub
29. Estudio de patrones de expresión por inmunohistoquímica de la proteína supresora tumoral BAP1 en melanoma cutáneo y su relación con parámetros clínico-patológicos e índice de proliferación celular
30. KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: “Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously”
31. Patients’ Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study
32. Utilità della citofluorimetria a flusso su liquido da BAL nella diagnosi di Istiocitosi a cellule di Langerhans (ICL)
33. Abstract P3-11-02: Evaluation of the effects of anticancer treatments in cancer patients undergoing SARS-COV2 vaccination (VAX-on study: Breast cancer subgroup analysis)
34. Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival
35. Metastatic anaplastic large cell lymphoma of the omentum presenting as an ulcerated nodule on the back.
36. Amiloidosis nodular cutánea que simula un tumor gigante
37. Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?
38. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
39. sj-docx-1-tam-10.1177_17588359211059873 ��� Supplemental material for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
40. Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives
41. Hipomelanosis macular progresiva: respuesta al tratamiento con minociclina
42. COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience
43. Additional file 1 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
44. Additional file 2 of Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
45. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
46. Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists
47. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
48. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
49. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade. The SePHER Study.
50. Multicohort and cross‐platform validation of a prognostic Wnt signature in colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.